E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
GHD+ISS in prepubertal children born at term or prematurely, AGA or SGA
GHD and SGA children (phase IV study) ISS children (phase III study) |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary objective: The hypothesis is that there will be a significant (p<0.05) difference in the proportion of children who have height close to the set goal: height SDS -0.5 after 3 years of GH treatment, when comparing the group treated with an individualized dose with the group of children treated with the fixed dose. |
|
E.2.2 | Secondary objectives of the trial |
To investigate whether the metabolic responses* correlate with the growth response, independently of the GH dose given in the group of children treated with individualised GH doses and to compare with levels in the group with fixed dose. (*IGF-I, IGFBP-3, fasting lipids, leptin, fasting insulin). To compare growth response to the changes in muscle, bone and fat mass measured with DEXA. To study the child’s quality of life/self esteem and cognitive performance, using psychological tests and questionnaires to the child, to the guardian(s) and teacher. To study effects of GH-treatment and genes found to be related to growth, i.e. point mutations and/or polymorphisms related to spontaneous growth and/or the response to GH treatment. A serum and DNA-sample from start of treatment will be stored, for later analyses in relation to observed effect of GH-treatment. Tertiary objective: To explore growth data in order to construct a prediction model for growth response based on pretreatment data. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Children, independent of their GH-secretion, with height below –2.0 SDS, (according to now used reference in Sweden, (14)) growing parallel or less to their growth channel during at least 1 year (ア 3 months) of observation (i.e. no ongoing spontaneous catch up growth). _ age at start of GH treatment 3- < 8 years (girls), 3- < 9 years (boys) _ bone age below 9 years according to Greulich and Pyle, centrally checked. _ known weight and length at start of GH treatment _ prepubertal at start of treatment: girls = B1, boys: testes < 3ml _ pre-treatment investigation performed: see 3.3.4 patient log _ in girls: normal karyotype Note: _ gestational age, birth size and parental heights are not inclusion criteria _ language performance is not an inclusion criteria for the growth study, only for the psychological part (optional)
|
|
E.4 | Principal exclusion criteria |
disease interacting with growth or syndrome, other than Silver-Russel Syndrome or appropriately treated hypothyroidism. _ ongoing catch-up growth before start of GH-treatment; measurements should be performed by trained persons, with the same technique during time period of at least 1 year. Definition: for inclusion growth should be ‘channel parallel’ or deviating downwards, i.e. change in height SDS during the pre-treatment year below + 0.3 SDS _ signs of foetal alcohol syndrome in the retina _ pathological body proportions, def sitting height % more than 2 SDS above or below normal. _ incapable of following the study protocol _ bad compliance during 1st year GH treatment (def: more than 24 missed injections 1st year on treatment) _ puberty (B2 or testes ³ 5ml)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Height after 3 years of treatment or onset of puberty |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
way of dosing:individual dosing contra standarddose/kg/day |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |